SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63276 354 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
63201US FDA recommends removal of hold on Sarepta's Elevidys in some patients ReOlecranon3July 28
63200FDA removes shipping hold for ambulatoryerippetoe1July 28
63199SRPT trading halted AH?erippetoe-July 28
63198Well GG, you were spot on about a $2 pop today. I almost think you’ve been manipOlecranon1July 28
63197As much as I would like to feel that optimism, I’m more pessimistic every day. POlecranon1July 28
63196That should be worth a $2+ pop. More importantly, it draws attention to this quaghettogoulash1July 28
63195Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag A top FDA appointee who dosukit3July 27
63194The Sarepta Mugging and Drug Innovation The Trump FDA tries to kill a therapy thsukit4July 27
63193Can anyone share the text from this article? Thanks The Sarepta Mugging and Drughettogoulash-July 27
63192Fwiw, Ingram said in May that it was the FDA who suggested adding Sirolimus to tghettogoulash3July 26
63191Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS BUSINESS WIRE Juluckydog881July 26
63190Thanks GG for posting this. What I found particularly interesting is that this mbodish1July 25
63189REUTERS Jul-25-2025 5:50 p.m. ET July 25 (Reuters) - The U.S. Food and Drug Adluckydog88-July 25
63188REUTERS Jul-25-2025 6:42 a.m. ET July 25 (Reuters) - Europe's medicines reluckydog881July 25
63187Great finds GG. AF’s prognistication that this could completely sink Sarepta seeOlecranon1July 25
63186Yet another mother explains the risk/reward elegantly. These Elevidys stories arghettogoulash2July 24
63185Roche also wonders wtf is up with the FDA. Meanwhile, Laura Loomer is on a crusaghettogoulash3July 24
63184Preceding that, more fake news: [graphic][graphic][graphic]ghettogoulash1July 24
63183found this hitting the wire at 3:22 Endpoints News Biotech/Pharma Reporter Zacluckydog882July 24
63182Added more SRPT a little while ago in the mid-10's. But I was afraid to buy Olecranon-July 24
63181SRPT: talk about a divergence of analyst opinions this morning ........ Citigrluckydog881July 24
63180Interesting that Goldman Sachs just downgraded IOVA (to $1.00), we all remember Stikkmann1July 24
63179Anyone following IOVA? Seems to be moving with good volume. Thoughts? TIACFL Invest 11July 22
63178I wasn't crazy about Sarepta defying FDA brass, but I could see why they didghettogoulash1July 22
63177CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (SRPT) , the leadluckydog88-July 21
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):